Remdesivir

'Soaring demand' of remdesivir, oxygen during 2nd wave of COVID-19: MHA

According to the annual report of the home ministry for 2021-22, during the second wave of coronavirus in the country, it had coordinated with the states and Union territories and various stakeholders concerned for ensuring the supply of medical oxygen for treatment of moderate to severe COVID-19 patients.

COVID-19 treatments for better protection against future variants identified

An international team led by researchers from the University of Kent in the UK and the Goethe-University in Germany tested the sensitivity of different SARS-CoV-2 Omicron and Delta viruses to combinations of the four currently approved antiviral drugs with betaferon.

As COVID-19 cases rise in Maharashtra, doctors say most patients have mild symptoms and fast recovery

The patients were being administered paracetamol, and not Remdesivir drug, which was used for patients in the first and second COVID-19 waves, they said.

India makes COVID-19 treatment drug Remdesivir 'freely exportable'

Until now, the Government of India used to allow restricted export of injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API) – a drug that is used in COVID-19 treatment.

New antiviral drug combo highly effective against COVID-19: Study

The research, published recently in the journal Nature, suggests that these drugs are more potent when used in combination than individually.

Economic Survey 2022| Govt initiative led to up to 89% fall in prices of key Covid devices

The prices of drugs and medical devices in India have long been under the scanner for unaffordability to a large chunk of the population but the government now claims that it is trying to fix a trade margin ceiling for many drugs, including the ones used in COVID treatment, to make them easily accessible to people.

Remdesivir to be used in patients with moderate to severe COVID-19: Health ministry

According to the clinical guidance issued by the Union health ministry for management of the infection in adult patients, Remdesivir has been asked to be used in patients with moderate to severe COVID-19 and those with no renal or hepatic dysfunction within 10 days of onset of any symptom.

Covid-19 Third Wave Preparations: 50 lakh Remdeivir in stock, 293 New Functional O2 Plants, 20 Lakh Beds

The 50 lakh vials of Remdesivir have been kept as a reserve for immediate release to states if the need emerges.

Drug firms seek free export of Remdesivir as weak demand inflates inventories

Drug makers had ramped up their capacity to make Remdesivir amid acute scarcity during the second wave of the coronavirus pandemic, but demand has crashed in step with the steep fall in the number of new cases.

COVID-19 update | Poor as well as multi-millionaire of 18 years, above to get free jabs: Centre to Supreme Court

A bench headed by Justice D Y Chandrachud had slammed the Centre's Covid vaccination policy, describing as "prima facie arbitrary and irrational" allowing states and private hospitals to charge those in the 18-44 age group while the jabs were offered free for groups in the first two phases, and ordered its review.

COVID-19 | Centre lifts ban on Remdesivir export, allows overseas sale sans authorisation

The export of Remdesivir injections and APIs against the Advance Authorization shall no longer require a separate export authorisation or permission as, under the revised policy, the drug has been moved from 'prohibited' to 'restricted' category.

Sun Pharma: Traction in speciality likely to sustain

Sun Pharma's key specialty products, particularly Ilumya (plaque psoriasis) and Cequa (dry eye disease), held up well

COVID-19: Centre discontinues remdesivir allocation to states, says supply is more than demand

The Ministry of Chemicals and Fertilizers said that the production of remdesivir had been ramped up ten times from 33,000 vials/day on April 11, 2021, to 3,50,000 vials/day on May 29.

Those indulging in black marketing of Remdesivir being booked under NSA: Yogi Adityanath

The Uttar Pradesh government will contain the second wave of COVID-19 by the end of May, Chief Minister Yogi Adityanath said.

Cipla — While COVID scope continues, watch out for FY23

Just when it seemed that Covid tailwinds are waning for Cipla, the drug maker has repositioned itself for the opportunities emerging from the second wave of the pandemic

Ideas for profit | Lupin: Focus on inhalation & biosimilars to aid margins in medium term

Possibility of positive developments on the product pipeline front and restructuring initiatives can accelerate earnings growth for Lupin. We continue to believe this opportunity is more suitable for investors with high risk appetite and those who are ready to hold it long enough for the product pipeline to unfold

Lupin: Focus on inhalation and bio-similars to aid margins in medium term

In the medium term, the focus is likely to be on the inhalation and biosimilar categories for Lupin, with scale-up in both US and European markets

Dr Reddy's signs licensing pact with Eli Lilly to produce COVID-19 treatment drug Baricitinib

The Hyderabad-based company has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly for the manufacture and marketing of the drug in India.

Cipla, Jubilant to face action if they fail to fulfill supply obligation of Remdesivir within 24 hours: Karnataka govt

The Karnataka government has said that the Centre had directed Jubilant Ltd to supply 32,000 Remdesevir vials to the state by May 9. However, Karnataka has only received 17,601 vials from the company as of May 8.

Remdesivir marketing companies to supply 53 lakh vials for April 21-May 16 period to states/ UTs: Govt

"The companies have been instructed to ensure timely supplies to all states/ UTs strictly as per the supply plan," the Ministry of Chemicals and Fertilizers said in a statement.

Eli Lilly India chief says company in talks with generic firms here on royalty free voluntary licensing of COVID-19 drug Baricitinib

They are also working with regulatory authorities and the government of India to donate Lilly’s COVID-19 treatments, including Baricitinib, if authorities deem it appropriate to potentially provide relief

COVID-19 second wave | Two flights carrying aid to India delayed till May 5, says US Department of Defense